NVIDIA's ReaSyn AI Revolutionizes Drug Discovery & Fluid AI Medical's Origin™ Gets FDA Nod - Life AI Weekly #36

Hi there,

Welcome to this week's edition of Life AI Weekly, where we delve into the latest advancements in Healthcare and Life Sciences AI. This week, we explore a range of exciting developments, including ScreenPoint Medical's AI technology, Transpara, which has been selected for the $16 million PRISM trial, aiming to enhance breast cancer screening. Additionally, Fluid AI Medical's innovative device, Origin™, has received FDA clearance, marking a significant step forward in medical device technology.

In other news, MindHYVE.ai has introduced ChironAI, a new tool designed to support clinical decision-making, while MIT has developed MultiverSeg for improved medical image annotation. These advancements highlight the ongoing integration of AI in healthcare, promising to improve patient outcomes and streamline medical processes. Stay tuned as we continue to bring you the latest updates in the world of AI-driven healthcare innovations.

AmplifyMD has raised $20 million in Series B funding led by Forerunner Ventures to enhance its AI-driven virtual care platform, aiming to improve clinical access and operational efficiencies.
Thyme Care has raised $97 million in Series D funding from investors including CVS Health and JPMorgan Chase. The company aims to improve cancer care using AI technology.

NVIDIA has introduced ReaSyn, a generative AI model designed to predict molecular synthesis pathways, enhancing drug and material development. Meanwhile, Viva Biotech received the 2025 APAC Technology Innovation Leadership Award from Frost & Sullivan for its AI-driven drug discovery platforms, showcasing significant advancements in preclinical R&D.

Rhode Island has announced the launch of Ocean State Labs, the state's first life science incubator, opening in early 2026. Avant Technologies, Inc. and Austrianova have formed Klothonova, Inc., a joint venture to develop AI-driven therapies for age-related diseases. Eli Lilly has opened a new Gateway Labs site in San Diego to support early-stage biotech companies with lab space and collaboration opportunities.

ScreenPoint Medical announced that its Transpara® breast imaging AI will be part of the PRISM Trial, a $16 million study funded by the Patient-Centered Outcomes Research Institute to assess AI's effectiveness in breast cancer screening.
MindHYVE.ai launched ChironAI, a Clinical Decision Support system utilizing the Ava-Healthcare AGI model to enhance healthcare intelligence with real-time analysis and recommendations.